RxDoctor Payments Data

Maribel Aguilera, MD

Psychiatry · Miami Lakes, FLNPI 1659343283

Payments from drug & device makers

$117,910in general payments, 2019–2025

Across 717 payments — averaging $164.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$103K
  • Axsome Therapeutics, Inc.$3K
  • Lundbeck LLC$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$2,0002%
  • Speaking & faculty fees$93,05079%
  • Travel & lodging$6,4866%
  • Food & beverage$16,22814%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,910 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$58,684
Medicare patients
89
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole78$121,849
VraylarCariprazine Hcl73$106,147
NuplazidPimavanserin Tartrate13$64,435
Invega SustennaPaliperidone Palmitate13$33,932
TrintellixVortioxetine Hydrobromide56$28,421
Aripiprazole193$14,243
AbilifyAripiprazole11$10,355
Clonazepam1,314$9,457
Loreev XrLorazepam20$8,697
FetzimaLevomilnacipran Hcl11$6,483
Buspirone Hcl473$6,481
Seroquel XrQuetiapine Fumarate13$5,941
Lurasidone Hcl31$4,863
Mirtazapine531$4,715
Quetiapine Fumarate ErQuetiapine Fumarate63$4,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,033$121,84978 claims
AbbVieVraylar, Fetzima$102,760$112,63084 claims
Johnson & JohnsonInvega Sustenna$1,177$33,93213 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$638$28,42156 claims
Almatica Pharma LLCLoreev Xr, Sertraline Hcl$525$10,856627 claims
E.r. Squibb & Sons, L.L.C.Abilify$169$10,35511 claims
Eisai Inc.Dayvigo$11$3,53911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Miami Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →